UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010564
Receipt number R000012357
Scientific Title A prospective cohort study to explore predictive factors to TS-1 plus platinum-based drugs in patients with squamous cell lung cancer YCRG10
Date of disclosure of the study information 2013/04/23
Last modified on 2018/10/29 08:50:38

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A prospective cohort study to
explore predictive factors to TS-1 plus platinum-based drugs in patients with squamous cell lung cancer
YCRG10

Acronym

A prospective cohort study to
explore predictive factors to TS-1 plus platinum-based drugs in patients with squamous cell lung cancer
YCRG10

Scientific Title

A prospective cohort study to
explore predictive factors to TS-1 plus platinum-based drugs in patients with squamous cell lung cancer
YCRG10

Scientific Title:Acronym

A prospective cohort study to
explore predictive factors to TS-1 plus platinum-based drugs in patients with squamous cell lung cancer
YCRG10

Region

Japan


Condition

Condition

squamous cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

The purpose of this study is to explore predictive factors whom treated with TS-1 plus platinum-based drugs(such as TS-1 plus Cisplatin or TS-1 plus Carboplatin) in chemotherapy-naïve patients with advanced squamous cell lung cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

To evaluate correlation between tumor response and gene expression and protein levels in serum,whole blood and tissue

Key secondary outcomes

To evaluate correlation between PFS, OS, adverse events, relative dose intensity and gene expression and protein levels in serum,whole blood and tissue


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Advanced squamous cell lung cancer patients(no prior chemotherapy) who is planned to receive TS-1 plus platinum-based drugs
2)Patients age is older than 20 when registration
3)Patients whoes blood samples(
serum and whole blood) are available before treatment
4)Target lesion is evaluable
5)Written infomed consent from the patients

Key exclusion criteria

Patients whose participation in this study is judged to be inappropriate by the physicians

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takeshi Kaneko

Organization

Yokohama City University Medical Center

Division name

Respiratory Disease Center

Zip code


Address

4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan

TEL

045-261-5656

Email

takeshi@med.yokohama-cu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masaharu Shinkai

Organization

Yokohama City University Medical Center

Division name

Respiratory Disease Center

Zip code


Address

4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan

TEL

045-261-5656

Homepage URL


Email

shinkai@yokohama-cu.ac.jp


Sponsor or person

Institute

Yokohama City University Medical Center

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

JAPAN


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

横浜市立大学附属市民総合医療センター(神奈川県)
横浜市立大学附属病院(神奈川県)
藤沢市民病院(神奈川県)
横浜船員保険病院(神奈川県)
横浜南共済病院(神奈川県)
国立病院横浜医療センター(神奈川県)
大和市立病院(神奈川県)
茅ヶ崎市立病院(神奈川県)
関東労災病院(神奈川県)
横浜栄共済病院(神奈川県)
神奈川県立がんセンター(神奈川県)
済生会横浜市南部病院(神奈川県)
横須賀市民病院(神奈川県)


Other administrative information

Date of disclosure of the study information

2013 Year 04 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2013 Year 02 Month 27 Day

Date of IRB


Anticipated trial start date

2013 Year 04 Month 24 Day

Last follow-up date

2016 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is designed to be prospective cohort study.
The purpose of this study is to explore predictive factors whom treated with TS-1 plus platinum-based drugs (such as TS-1 plus Cisplatin or TS-1 plus Carboplatin) in chemotherapy-na&iuml;ve patients with advanced squamous cell lung cancer.
To evaluate correlation between response and gene expression, we could estimate the population of sensitive patients to TS-1 plus platinum-based treatment.
50 patients is planned to be registered.(TS-1+CBDCA:25patients,TS-1+CDDP:25patients)
Continue until progression disease or unfeasible adverse events.


Management information

Registered date

2013 Year 04 Month 23 Day

Last modified on

2018 Year 10 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012357


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name